The Neuropathological Hallmarks of Alzheimer’s Disease

August 24, 2021Henry Peck

Neuropathology, or the study of diseases of the brain, spinal cord, and nerves, plays an important role in characterizing the pathogenesis of neurodegenerative diseases, such as Alzheimer’s disease. Neuropathological hallmarks, or characteristics, of Alzheimer’s disease consist of positive and negative lesions. Positive lesions include tau hyperphosphorylation, neurofibrillary tangles, beta-amyloid plaques, cerebral amyloid angiopathy, and glial responses, while negative lesions include neuronal and synaptic loss.

Below, we take a deeper look into these neuropathological hallmarks and how they affect the brains of individuals diagnosed with Alzheimer’s disease or other forms of dementia.

Positive Lesions Associated with Alzheimer’s Disease

Detailed below are positive lesions associated with Alzheimer’s disease, including tau hyperphosphorylation, neurofibrillary tangles, beta-amyloid plaques, cerebral amyloid angiopathy, and glial responses. 

Tau Hyperphosphorylation and Neurofibrillary Tangles

Tau, a microtubule-associated protein, is normally located on the axon and plays a helpful role in the brain, physiologically facilitating axonal transport by binding and stabilizing microtubules that help guide nutrients and molecules from the cell body to the axon and dendrites. However, in individuals with Alzheimer’s disease, tau becomes altered and forms neurofibrillary tangles within nerve cells up to 15 years before symptom onset. This alteration involves the translocation of tau to some somatodendritic compartments and hyperphosphorylation, misfolding, and aggregation of tau. Neurofibrillary tangles are intraneuronal aggregates of this hyperphosphorylated, misfolded tau which block the neuron’s transport system, harming the synaptic communication between neurons.

Tau is an emerging and newly understood element of the pathophysiological biomarker landscape. Similar to reducing beta-amyloid plaques, the inhibition of the tau abnormality is another highly promising therapeutic approach to Alzheimer’s disease and other tau pathologies. 

Amyloid Plaques

Amyloid plaques are extracellular deposits of beta-amyloid peptides and are a distinct pathology of Alzheimer’s. Beta-amyloid proteins originate from a larger protein, amyloid precursor protein, found in the fatty membrane surrounding the nerve cells. Beta-amyloid is produced in all individuals and is naturally removed by the body before it can become harmful to the brain. However, for individuals with Alzheimer’s disease, it is not removed, and the beta-amyloid proteins stick or clump together, eventually forming a plaque that cannot be broken down. Beta-amyloid proteins begin to collect in the brains of individuals with Alzheimer’s disease up to 20 years before symptoms appear. As time goes on, these plaques begin to form in other parts of the brain responsible for cognitive function.

The discovery of beta-amyloid plaques and their relationship to Alzheimer’s disease led to the ability to provide earlier diagnoses of the disease through amyloid PET scans and recently, the potential to target and reduce such plaques to delay clinical decline.

Cerebral Amyloid Angiopathy

Another neuropathological hallmark of Alzheimer’s disease is cerebral amyloid angiopathy, which is characterized by deposits of beta-amyloid in the tunica media of leptomeningeal arteries, cortical capillaries, small arterioles, and medium-sized arteries in the posterior regions of the brain. Some level of cerebral amyloid angiopathy, which is often mild, is present in around 80% of Alzheimer’s patients. Individuals with severe cerebral amyloid angiopathy may experience vessel wall weakening, which can ultimately lead to lobar hemorrhage.

Glial Responses

Glial cells are the most abundant cells in the brain, outnumbering neurons by approximately 10:1, and come in many forms, including microglia and astrocytes. Glial cells, and their relationship with neurons, are fundamental for brain function. Glia are critical for normal central nervous system functioning as well as its dysfunction, as they are directly related to all forms of neuropathological processes. Thus, the progression and outcome of neurocognitive and neurodegenerative diseases, including Alzheimer’s, depend on glial responses.

In healthy brains, microglia engulfs and destroys waste, debris, and protein buildup, including beta-amyloid plaques. However, in individuals with Alzheimer’s, microglia cells fail to clear waste and toxins in the brain. Similarly, astrocytes are typically signaled to remove and clear the remaining plaque buildup and cellular debris but do not do so in those with Alzheimer’s disease.

Negative Lesions Associated with Alzheimer’s Disease

Neuronal and synaptic losses are characterized as negative lesions and are neuropathological hallmarks of Alzheimer’s disease. In individuals with Alzheimer’s disease, neurons become injured and die throughout the brain, causing connections between neural networks to break down which can result in shrinkage of regions of the brain. 

Dynamic gain and loss of synapses are essential for healthy brain function. However, for individuals with Alzheimer’s, there are disruptions in the mechanics of neuronal plasticity which eventually results in a net loss of synapses. Synaptic loss is indicated as an early pathological event in Alzheimer’s disease and is believed to be driven by beta-amyloid and tau pathology.

New Identification Methods for Neuropathological Hallmarks of Alzheimer’s Disease

While many of the neuropathological hallmarks of Alzheimer’s disease provide a window to indicate the presence of Alzheimer’s before clinical onset, they are typically identified through expensive, time-consuming, and invasive procedures, such as amyloid PET scans and cerebrospinal fluid extraction and analysis.

Altoida is developing a precision neurology device to measure and analyze nearly 800 cognitive and functional digital biomarkers associated with cognitive impairment. Users complete a set of hyper-realistic augmented reality activities that are designed to place the user’s brain under a cognitive load representative of real-world tasks on any smart device in roughly 10 minutes. With data across 11 unique neurocognitive domains and innovative artificial intelligence, Altoida’s device will pioneer predictive diagnosis of neurological disease to help identify individuals that may have neuropathological hallmarks of Alzheimer’s disease.

To learn more about the neuropathological hallmarks of Alzheimer’s disease and Altoida’s precision neurology device, contact us today.

Contact Us

At Altoida, we use digital biomarkers to radically change the method of assessing brain health and cognitive diseases. After nearly two decades of research, we are developing a platform and device to measure and analyze cognitive biomarkers associated with cognitive impairment to evaluate perceptual and memory function.
Contact Us

Contact Us

80 M Street SE, Suite 100 Washington, DC 20003 USA 


Follow Us


By visiting our Website and/or using the Services in any manner, you acknowledge that you accept the practices and policies outlined in our Privacy Policy.
@ Altoida 2021